The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Capecitabine; Cisplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms EXPRESS-GC
- 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
- 02 Jul 2014 New trial record